Navigation Links
New Study of Concerta(R) Showed Significant Improvement of ADHD Symptom Management in Adults Compared to Placebo
Date:10/26/2007

eeting pre-defined Responder criteria (p=0.009).

In the study, 229 patients with ADHD aged 18-65 years were randomized to receive CONCERTA(R) 36-108 mg/day or placebo, for seven weeks. The final analysis set contained data from 226 patients(a). Patients in the CONCERTA(R) group received a starting dose of 36 mg/day and the dose was increased in 18 mg increments every seven days (+/-2 days) for up to five weeks until response (AISRS scores decreased by 30% and CGI-I rating of 1 "very much" or 2 "much" improved) was achieved or titration to the maximum dose of 108 mg. The dose could be reduced one time during the study for tolerability reasons. The mean final dose was 67.7 mg/day.

Adverse events were reported by 93 (84.5%) of patients in the CONCERTA(R) group compared with 74 (63.8%) in the placebo group. The most commonly reported adverse events with CONCERTA(R) included decreased appetite (25.5%), headache (25.5%), dry mouth (20%), anxiety (16.4%), nausea (12.7%), increased blood pressure (10%), insomnia (9.1%), initial insomnia (7.3%), increased heart rate (7.3%), bruxism (6.4%), irritability (6.4%) and muscle tightness (6.4%). There were no serious treatment emergent adverse events reported and 16 (14.5%) and 6 (5.2%) subjects in the CONCERTA(R) and placebo groups, respectively, discontinued due to adverse events.

Today's data presentation included interim results from a long-term, open-label safety study. A similar dose titration protocol was used as in the double-blind study during the first weeks of the study after which the dose was flexible within the range of 36 to 108 mg. Interim results show that CONCERTA(R) was well tolerated in an adult population with ADHD in a dose range from 36mg to 108 mg per day for up to six months.

About ADHD

Attention Deficit Hyperactivity Disorder (ADHD) is a common and treatable neuropsychiatric condition, which includes inattention, hyperactivity and impulsivity. According to the National Institut
'/>"/>

SOURCE McNeil Pediatrics
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Data Available From Erbitux Phase III Study in First-Line Treatment of Advanced Lung Cancer
2. Clinical Study Shows Regenecare Relieves Pain and Itching of Skin Rashes Caused by Widely Used Cancer Drugs
3. Cell Therapeutics, Inc. Management to Discuss Todays Announcement of Interim Pixantrone Study Results
4. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy of BF-200 ALA In Actinic Keratosis
5. Reaction to Avandia Warnings Stronger Among Internists Than Endocrinologists, According to Study by GfK Market Measures
6. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
7. Actemra (tocilizumab) Third Phase III Study Results Show Significant Improvement in Symptoms of Patients with Rheumatoid Arthritis
8. Protox Announces Positive Clinical Data from Prostate Cancer Study
9. International ENDORSE Study Shows That the Majority of Hospitalized Patients Surveyed are at Risk for VTE and Many do not Receive Recommended VTE prophylaxis
10. New Study Shows That Extending Prophylaxis With Clexane / Lovenox (enoxaparin Sodium Injection) to 5 Weeks is More Effective Than 10 Days for Reducing the Risk of Venous Thromboembolism (VTE) in Acutely ill Medical Patients With Reduced Mobility
11. Genzyme Announces Data from First Phase 3 Study of Tolevamer in Patients with C. difficile Associated Diarrhea
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/31/2015)... 2015  Chiasma, Inc. (NASDAQ: CHMA ), ... for the orphan condition acromegaly, today reported financial ... 2015 and provided a corporate update. ... time for Chiasma, as we successfully completed our ... first New Drug Application (NDA) has been accepted ...
(Date:8/31/2015)... 2015 With increasing clinical applications, the ... rise in active partnerships. The primary reason for ... quantitate CD4 cell markers in human immunodeficiency virus ... New analysis from Frost ... Market ( http://www.frost.com/nf0e ), finds the market earned ...
(Date:8/31/2015)... Aug. 31, 2015  The departments of Drug and ... at Gaudenzia Concept 90 to raise awareness for International ... in Pennsylvania and help more ... on recovery through the Building Bridges to Recovery ... dying every day to a disease that is fully ...
Breaking Medicine Technology:Chiasma Reports Second Quarter 2015 Financial Results and Recent Business Highlights 2Chiasma Reports Second Quarter 2015 Financial Results and Recent Business Highlights 3Chiasma Reports Second Quarter 2015 Financial Results and Recent Business Highlights 4Chiasma Reports Second Quarter 2015 Financial Results and Recent Business Highlights 5Chiasma Reports Second Quarter 2015 Financial Results and Recent Business Highlights 6Chiasma Reports Second Quarter 2015 Financial Results and Recent Business Highlights 7Chiasma Reports Second Quarter 2015 Financial Results and Recent Business Highlights 8Chiasma Reports Second Quarter 2015 Financial Results and Recent Business Highlights 9Clinical Applications of Flow Cytometry Instrumentation and Reagents are Transforming this Market with a High-Growth Path 2Clinical Applications of Flow Cytometry Instrumentation and Reagents are Transforming this Market with a High-Growth Path 3Clinical Applications of Flow Cytometry Instrumentation and Reagents are Transforming this Market with a High-Growth Path 4Pennsylvania Departments of Drug & Alcohol Programs and Health Kick-off Second Annual Building Bridges to Recovery Initiative 2
... Identify Unique microRNA Signatures That Will ... Project Will Leverage Rosetta Genomics, Proprietary microRNA Extraction, and Quantification Technologies, ... and Experience ... Patients With High Risk, of Recurrence, who may Benefit From Adjuvant ...
... Accrual and Expansion Plans for SB-509-701 Phase 2 Clinical Trial for ... ... Neuropathy, SAN FRANCISCO, June 6 Sangamo BioSciences,Inc. (Nasdaq: SGMO ... trial (SB-509-701) in subjects with moderate to,severe diabetic neuropathy. Additionally, based upon ...
Cached Medicine Technology:Rosetta Genomics and M. D. Anderson to Develop a MicroRNA-based Diagnostic Test to Identify Risk of Recurrence of Lung Cancer 2Rosetta Genomics and M. D. Anderson to Develop a MicroRNA-based Diagnostic Test to Identify Risk of Recurrence of Lung Cancer 3Rosetta Genomics and M. D. Anderson to Develop a MicroRNA-based Diagnostic Test to Identify Risk of Recurrence of Lung Cancer 4Rosetta Genomics and M. D. Anderson to Develop a MicroRNA-based Diagnostic Test to Identify Risk of Recurrence of Lung Cancer 5Sangamo BioSciences Provides Update on Diabetic Neuropathy Clinical Programs 2Sangamo BioSciences Provides Update on Diabetic Neuropathy Clinical Programs 3Sangamo BioSciences Provides Update on Diabetic Neuropathy Clinical Programs 4Sangamo BioSciences Provides Update on Diabetic Neuropathy Clinical Programs 5
(Date:8/31/2015)... Los Angeles, CA (PRWEB) , ... August 31, 2015 , ... ... August 16 by CDA Press, the expert guest author addressed the topic of treating ... The author explained that, while steroids were shown to slightly improve physical function in ...
(Date:8/31/2015)... ... August 31, 2015 , ... Wound Care Advantage, a leader ... Introduction to Hyperbaric Medicine Course. The next UHMS approved 40-hour Introduction to Hyperbaric ... in Long Beach, CA. The meeting is open for registration from physicians, clinicians ...
(Date:8/31/2015)... Metamora, Michigan (PRWEB) , ... August 31, 2015 ... ... launched a new weight management program that is unique to the Lake Orion ... in Oakland and Macomb County. , WEmovestrong’s weight management program will incorporate ...
(Date:8/31/2015)... Michigan (PRWEB) , ... August 31, 2015 , ... ... pre and postnatal fitness classes. , Starting September 1st they are ... called "The Mom Bod" and "Healthy Body, Healthy Baby." , More information can ...
(Date:8/31/2015)... Angeles, CA (PRWEB) , ... August 31, 2015 , ... ... start from and those who are interested in learning more about the procedure beyond ... Parsa Mohebi. , Internationally recognized hair transplant surgeon Parsa Mohebi will be on ...
Breaking Medicine News(10 mins):Health News:Article on Steroid Use for Back Pain Highlights the Effectiveness of Surgery in Treating Disk Pain, says Dr. Seyed M. Rezaian 2Health News:Registration Opens for Wound Care Advantage’s Second UHMS Approved 40-Hour Introduction to Hyperbaric Medicine Course 2Health News:Registration Opens for Wound Care Advantage’s Second UHMS Approved 40-Hour Introduction to Hyperbaric Medicine Course 3Health News:Registration Opens for Wound Care Advantage’s Second UHMS Approved 40-Hour Introduction to Hyperbaric Medicine Course 4Health News:Watch a Live Hair Transplant at Parsa Mohebi Hair Restoration’s Open House 2
... agent selumetinib has shown promising results in people with ... led by cancer researchers at The Ohio State University. ... protein called MEK, which cancer cells need to proliferate ... lining the bile ducts and gall bladder. About 100,000 ...
... By Kathleen Doheny HealthDay Reporter , MONDAY, ... that report the greatest number of satisfied inhabitants also ... Seemingly contradictory, the findings are probably explained by ... constantly compare oneself to others. "Deep down we ...
... will gather at Rice University,s Shepherd School of Music ... cognition and behavior and present the latest research findings ... a series of in-depth morning seminars, the scientific researchers ... the musicians learn concurrently about brain morphology, music perception ...
... MONDAY, April 25 (HealthDay News) -- New research suggests that ... regulating a brain wave known as the alpha rhythm, which ... small study, researchers found that those participants using meditation were ... told where to direct their attention -- after they finished ...
... association between computer and Internet use in adolescents and ... drunkenness and unprotected sex. "This research is based ... engaged in a behaviour is a way of learning ... candidate in School of Kinesiology and Health Studies. "Since ...
... examines the ion selectivity of cation-selective channels and transporters. ... the Journal of General Physiology ( www.jgp.org ... his introduction, a key tool in most recent studies ... which emphasize the fluid-like features of the selectivity filter ...
Cached Medicine News:Health News:Targeted agent selumetinib shows promise in biliary cancer 2Health News:'Happiest' States Show Highest Suicide Rates: Study 2Health News:'Happiest' States Show Highest Suicide Rates: Study 3Health News:Musicians and scientists to research mind and music at Rice University conference 2Health News:Meditation May Help Brain Block Out Distractions 2
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
Medicine Products: